Abbott Laboratories (ABT) said Monday it has reached a settlement with DexCom (DXCM) to resolve all outstanding patent disputes related to continuous glucose monitoring products.
The details of the settlement remain confidential but Abbott said there are no financial payments involved in the agreement.
Abbott also said the settlement would lead to the dismissal of all pending cases in courts and patent offices worldwide. The settlement also included a provision that neither company would litigate patent, trade dress nor design rights disputes for the next 10 years.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.